Dengue Fever

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It must not replace individualized patient assessment, clinical judgment, or consultation with current local and international guidelines. Drug dosages and therapeutic recommendations are subject to change and must always be cross-referenced with approved prescribing information.

---

Overview

Definition

Dengue fever (DF) is an acute, systemic mosquito-borne viral illness caused by four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) of the dengue virus, an RNA virus belonging to the Flaviviridae family. It ranges in severity from asymptomatic infection or mild self-limiting fever (Dengue Fever) to severe, potentially fatal forms characterized by plasma leakage, hemorrhage, and organ failure (Severe Dengue, formerly Dengue Hemorrhagic Fever/Dengue Shock Syndrome).

Epidemiology

• Global Burden: Endemic in over 100 countries, primarily in tropical and subtropical regions. Approximately half of the world's population is at risk.
• Incidence: Estimates suggest 100 to 400 million infections occur annually, though most are mild or subclinical.
• Vector: Transmitted primarily by the female Aedes aegypti mosquito, and less commonly by Aedes albopictus.
• Seasonality: Typically correlates with rainy seasons, which favor mosquito breeding.
• Serotypes: Infection with one serotype provides long-lasting homologous immunity but only temporary (few months) heterologous immunity. Subsequent infection with a different serotype (secondary heterologous infection) significantly increases the risk of Severe Dengue.

Classification (WHO 2009 Classification)

The WHO scheme emphasizes pragmatic management based on clinical severity and identifies those at risk of severe disease.

Group	Subgroup	Description	Management Setting
Group A	Dengue without Warning Signs	Mild illness, likely to recover rapidly. Includes patients with no underlying risk factors.	Outpatient
Group B	Dengue with Warning Signs	Patients with abdominal pain/tenderness, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy/restlessness, liver enlargement (>2 cm), or increasing hematocrit concurrent with rapid drop in platelet count.	Inpatient monitoring (Hospitalization required)
Group C	Severe Dengue	Patients meeting criteria for one or more of the following: 1) Severe plasma leakage leading to shock (Dengue Shock Syndrome) and/or fluid accumulation with respiratory distress. 2) Severe bleeding (as evaluated by the clinician). 3) Severe organ involvement (e.g., AST/ALT $\ge 1000$ IU/L, impaired consciousness, myocarditis).	Critical Care (ICU)

---

Pathophysiology

Mechanism

The pathogenesis of Severe Dengue (plasma leakage and coagulopathy) is complex and largely attributed to increased vascular permeability rather than direct viral toxicity.

1. Viral Replication: Following inoculation, the virus replicates in host cells (macrophages, dendritic cells, monocytes).
2. Immune Response and Cytokine Storm: In the early phase, viremia triggers both innate and adaptive immune responses. T-cell activation and the release of inflammatory cytokines (e.g., TNF-$\alpha$, IL-6, IL-8) occur.
3. Antibody-Dependent Enhancement (ADE): Crucially, in secondary heterologous infections, pre-existing sub-neutralizing antibodies from the first infection bind to the new serotype. These immune complexes are efficiently internalized by Fc-$\gamma$ receptor-bearing cells (monocytes/macrophages). This ADE effect dramatically increases viral load within target cells, leading to a massive release of pro-inflammatory mediators.
4. Endothelial Dysfunction: Systemic inflammatory mediators and viral components damage the vascular endothelium, leading to dysfunction of the glycocalyx layer and disruption of tight junctions.
5. Plasma Leakage: This increased microvascular permeability allows plasma components (albumin, fluid) to leak into the extravascular space (third space), resulting in hemoconcentration, hypovolemia, shock, and pleural or abdominal effusions.
6. Coagulopathy: Thrombocytopenia is common due to decreased production, peripheral destruction, and consumption. Capillary fragility, impaired platelet function, and in severe cases, DIC, contribute to hemorrhagic manifestations.

Risk Factors

• Secondary Heterologous Infection: The single strongest risk factor for Severe Dengue.
• Host Factors: Infants, the elderly, patients with chronic conditions (diabetes, bronchial asthma, sickle cell disease), obesity, and high body mass index.
• Virus Serotype: DENV-2 and DENV-3 are frequently associated with more severe disease compared to DENV-1 and DENV-4, although all serotypes can cause severe disease.

Protective Factors

• Homologous Immunity: Previous infection with the same serotype (long-term protection).
• Vaccination (Dengvaxia): Available in endemic areas for individuals with confirmed previous dengue infection (seropositive), aged 9-45 years, to reduce the risk of severe disease. Note: Vaccination in seronegative individuals carries a higher risk of severe disease upon subsequent natural infection and is contraindicated.

---

Clinical Presentation

The illness is divided into three phases: Febrile, Critical, and Recovery.

Signs and Symptoms

Cardinal Features (Febrile Phase: Day 0–5)

• High-grade fever: (39–40°C or 102–104°F) typically abrupt onset, continuous.
• Severe headache (often frontal).
• Retro-orbital pain.
• Myalgia and Arthralgia: Often described as "breakbone fever."
• Rash: Flushing, transient generalized erythema, often followed by a maculopapular or confluent petechial rash later in the critical phase.
• Minor hemorrhagic manifestations: Petechiae, positive tourniquet test.

Early Signs (Febrile Phase)

• Early facial flushing, mild conjunctival injection.
• Anorexia, nausea, vomiting.
• Pharyngeal/oral mucosal congestion.

Advanced Signs (Critical Phase: Day 3–7)

This phase commences when the fever drops (defervescence), which paradoxically signals the onset of potential severe illness. * Warning Signs (WHO Group B): * Severe, persistent abdominal pain or tenderness (often RLQ/RUQ). * Persistent vomiting ($\ge 3$ times in 1 hour or $\ge 4$ times in 6 hours). * Mucosal bleeding (gingival bleeding, epistaxis, menorrhagia). * Lethargy or restlessness. * Clinical evidence of fluid leakage (pleural effusion, ascites) or increasing hematocrit. * Hepatomegaly (tender, $>2$ cm below costal margin). * Signs of Severe Dengue (WHO Group C): * Shock: Rapid, weak pulse; narrow pulse pressure ($\le 20$ mmHg); hypotension; cold, clammy extremities (Dengue Shock Syndrome). * Severe Bleeding: Gastrointestinal bleeding (hematemesis, melena), massive cutaneous hemorrhage, requirement for transfusion. * Severe Organ Impairment: * Neurological: Seizures, altered mental status (encephalopathy/encephalitis). * Hepatic: Jaundice, severe transaminitis (AST/ALT $\ge 1000$ IU/L). * Cardiac: Myocarditis.

Atypical Presentations

• Dengue Encephalopathy: Direct viral invasion or secondary effects of shock/organ failure.
• Acalculous Cholecystitis.
• Hemophagocytic Lymphohistiocytosis (HLH).
• Acute Renal Failure (AKI).

Physical Examination

Inspection

• Febrile/Critical Phase: Skin flushing, petechiae, purpura, rash.
• Critical Phase (Plasma Leakage): Periorbital edema, signs of hydration status (sunken eyes, dry mucous membranes vs. peripheral edema from aggressive fluid resuscitation), signs of pleural effusion/ascites.
• Severe Dengue: Signs of shock (pallor, cyanosis, cold extremities).

Palpation

• Gastrointestinal: Tender hepatomegaly, abdominal tenderness (generalized or localized).
• Circulatory: Assessment of peripheral perfusion, capillary refill time ($\text{Normal: } <2 \text{ seconds}$), weak/thready pulse.
• Pulse Pressure: A narrowing pulse pressure ($\le 20\text{ mmHg}$) is an early and critical sign of impending shock.

Special Tests

• Tourniquet Test (Rumpel-Leede Test): Apply blood pressure cuff to the forearm for 5 minutes at midpoint between systolic and diastolic pressure. Positive if $\ge 20$ petechiae per square inch ($2.5 \times 2.5\text{ cm}^2$). While suggestive, it is not diagnostic or prognostic.

---

Diagnostic Approach

The diagnosis is primarily clinical in an endemic area during an outbreak, but laboratory confirmation is essential.

History Taking

Key Questions

• Travel/Residence: History of travel to dengue-endemic areas within the past 14 days.
• Onset and Course of Fever: Clear timing of onset (Day of Illness is crucial).
• Warning Signs: Specific inquiry about persistent vomiting, severe abdominal pain, and lethargy, especially upon defervescence.
• Bleeding: Ask specifically about epistaxis, gingival bleeding, excessive menstrual bleeding, petechiae, and GI bleeding.
• Fluid Intake and Urine Output: Vital signs for assessing hydration (oliguria is a warning sign).
• Prior Dengue Infection: History of previous infection (increases risk of severe disease).

Red Flags (Require Immediate Hospitalization)

1. Day 3–7 of illness (Critical Phase) with sudden temperature drop.
2. Any Warning Sign (See $4.1.3$).
3. Co-morbidities: Pregnancy, infancy, extreme age, obesity, chronic diseases (e.g., CKD, CAD).
4. Socio-economic factors: Living alone, difficulty accessing health care, or inability to manage oral fluid intake at home.

Laboratory Tests

First-Line (Initial Diagnosis and Monitoring)

Test	Timing (Days)	Interpretation	Clinical Utility
Dengue NS1 Antigen (Nonstructural protein 1)	0–7	Positive suggests acute infection. High sensitivity in the first 5 days.	Rapid diagnosis, useful during the febrile phase.
Complete Blood Count (CBC)	Daily/Twice Daily (Critical Phase)	Leukopenia (common). Thrombocytopenia (usually peaks Day 4–7). Hemoconcentration: Hematocrit (Hct) increase $\ge 20\%$ above baseline indicates plasma leakage.	Crucial for monitoring the critical phase and guiding fluid resuscitation.
Liver Enzymes (AST/ALT)	Critical Phase	Mild elevation is common. AST is typically higher than ALT. Elevation $\ge 1000$ IU/L indicates severe organ involvement.	Assess severity and monitor potential hepatic dysfunction.

Confirmatory (Serology)

Test	Timing (Days)	Interpretation	Clinical Utility
Dengue IgM antibody	After Day 5	Positive suggests recent primary or secondary infection. Rises rapidly around Day 5–7.	Confirms recent infection (useful in recovery phase or when NS1 is negative late).
Dengue IgG antibody	After Day 7	High Titer suggests previous infection. Rising Titer (4-fold or more) in paired samples (acute vs. convalescent) confirms current infection. High IgG/low IgM ratio suggests secondary infection.	Confirms recent infection status; helps differentiate primary vs. secondary infection.
RT-PCR (Reverse Transcriptase–Polymerase Chain Reaction)	0–7	Positive confirms viremia and serotype.	Research, serotype surveillance, and definitive early diagnosis.

Monitoring (During Critical Phase)

• CBC with Hct: Every 4–6 hours if unstable, or daily/BID if stable (critical for fluid management).
• Electrolytes, Creatinine, BUN: To monitor for AKI, especially in shock.
• Coagulation Profile (PT/aPTT/Fibrinogen): Indicated if active bleeding or signs of DIC.

Imaging

Recommended

• Bedside Ultrasound (POCUS): Highly practical and recommended during the critical phase.
  • Purpose: To detect and quantify localized fluid accumulation indicative of plasma leakage (pleural effusion, ascites, thickened gallbladder wall). Gallbladder wall thickening (>3 mm) is an early, highly sensitive sign of leakage.
  • Chest X-ray (CXR): To confirm significant pleural effusion (usually unilateral, right-sided).

Advanced

• CT/MRI: Reserved for assessment of severe organ involvement, particularly to evaluate for intracranial bleeding (e.g., in patients with refractory altered mental status or focal neurological deficits).

---

Management

Dengue management is primarily supportive, focusing on meticulous fluid balance and hemodynamic monitoring, especially during the Critical Phase (Day 3–7).

Acute Management (Based on WHO 2009 Grouping)

Group A: Dengue without Warning Signs (Home Care)

• Immediate: Encourage oral rehydration (ORS, water, fruit juice). Rest.
• Pharmacological: Paracetamol (Acetaminophen) for fever/pain. Avoid NSAIDs (Ibuprofen, Naproxen) and Aspirin due to increased bleeding risk.
• Monitoring: Educate patient/family on warning signs and the importance of hydration. Advise daily follow-up and urgent return during defervescence (Day 3–7).

Group B: Dengue with Warning Signs (Hospitalization/Close Observation)

• Stabilization: Intravenous (IV) fluid therapy is initiated if the patient cannot tolerate oral fluids or shows signs of dehydration.
• Fluid Regimen (Crystalloids): Initiate an initial fluid challenge with isotonic crystalloids (e.g., Normal Saline, Ringer's Lactate).
  • Initial Bolus: $5–7 \text{ mL/kg/hour}$ over $1–2$ hours.
  • Recheck Hct: If Hct decreases but the patient remains unstable, consider bleeding. If Hct remains high or increases, continue fluids.
  • Maintenance: Titrate fluid rate down based on clinical and laboratory improvement (stable vital signs, adequate urine output $>0.5 \text{ mL/kg/hour}$, decreasing Hct). Taper progressively: $3 \text{ mL/kg/hr}$, then $2 \text{ mL/kg/hr}$, and finally switch to oral fluids as leakage ends (usually $\sim 24–48$ hours).

Group C: Severe Dengue (Critical Care/ICU Management)

• Emergency (Shock Management): Recognize and treat shock immediately.
  • Initial Bolus (Rapid): $10 \text{ mL/kg}$ of isotonic crystalloid over $15–30$ minutes.
  • Reassessment (Every $15–30\text{ minutes}$): Check vital signs, peripheral perfusion, and Hct.
    • If improvement: Reduce fluid rate to $5–7 \text{ mL/kg}$ over 1 hour, then gradually taper.
    • If NO improvement and Hct is high (evidence of leakage): Repeat the $10 \text{ mL/kg}$ bolus over $15–30\text{ minutes}$. Repeat up to 3 times.
• Beyond Crystalloids (Refractory Shock Management):
  • If Hct remains high/rising after 3 boluses: Consider colloid solution (e.g., Dextran 40, Gelatin) $10 \text{ mL/kg}$ over $1–2$ hours. Colloid use should be limited due to concerns about worsening outcomes if overused.
  • If shock persists despite fluid resuscitation AND Hct drops (or is already low $\le 35\%$): Suspect internal bleeding. Requires prompt cross-matching and transfusion of Packed Red Blood Cells (PRBCs) $5–10 \text{ mL/kg}$.
  • Platelet/FFP Transfusion: Routine prophylactic transfusion for thrombocytopenia is not recommended unless the patient is actively bleeding, or if platelets are extremely low $(<10,000/\text{mm}^3)$ and the patient has high risk of bleeding (e.g., pre-procedure).

Chronic Management (Recovery Phase)

• Diuresis: The leakage phase is self-limiting (usually 24–48 hours). The recovery phase is marked by fluid reabsorption (diuresis). Overhydration can lead to pulmonary edema and respiratory distress. Fluid infusion must be stopped or significantly reduced at this stage.
• Monitoring: Daily monitoring of total fluid intake/output, Hct, and clinical signs of reabsorption.

Treatment Algorithms

First-Line (Fluid Management Paradigm)

The primary goal is the prompt recognition and replacement of fluid losses due to plasma leakage, while avoiding excessive fluid.

1. Assess Severity: Use WHO classification (A, B, or C).
2. Monitor Hct: The Hct trend is the most critical guide for fluid management.
   • Rising Hct: Indicates need for more fluid.
   • Falling Hct (after stabilizing/falling previously): Indicates fluid recovery, or bleeding if hemodynamically unstable.
3. Administer Fluid (Crystalloids preferred): Follow staged protocol, decreasing rate as signs of leakage resolve.

Second-Line (Supportive Care)

• Transfusion: For significant hemorrhage (guided by Hct and hemodynamic stability).
• Vasopressors/Inotropes: Used only if shock persists despite adequate fluid resuscitation and correction of bleeding.

Refractory Cases

• Consider other shock etiologies: Distributive shock (sepsis), cardiogenic shock (myocarditis).
• Refractory Shock: May require massive transfusion protocol for severe hemorrhage, or invasive hemodynamic monitoring (e.g., arterial line, CVP) to guide pressor and fluid use.

---

Complications

Common

• Dehydration: Especially in the febrile phase due to fever, vomiting, and early fluid loss.
• Hemorrhage: Mucosal (gingival, epistaxis), minor skin bleeding.

Serious

• Dengue Shock Syndrome (DSS): Circulatory failure due to profound plasma leakage.
• Severe Hemorrhage: Gastrointestinal bleeding (most common cause of death related to bleeding).
• Severe Organ Impairment (Severe Dengue):
  • Encephalopathy/Encephalitis: Altered consciousness, seizures.
  • Acute Liver Failure: Severe transaminase elevation and coagulopathy.
  • Myocarditis/Cardiomyopathy: Transient cardiac dysfunction.
  • Pulmonary Edema/Acute Respiratory Distress Syndrome (ARDS): Usually due to aggressive fluid resuscitation in the leakage or recovery phase.

Long-term

• Post-Dengue Chronic Fatigue: May last for several weeks or months.
• Neurocognitive deficits: Rarely reported following severe central nervous system involvement.

---

Prognosis

Factors Affecting Outcome

Poor Prognostic Indicators: Delayed presentation, rapid defervescence to shock, secondary infection, extreme age (infants/elderly), underlying chronic illnesses, rapid decline in platelet count accompanied by a steep rise in Hct, and presence of severe organ involvement.

Survival

• With early recognition and aggressive, tailored supportive care, mortality in specialized centers is $<1\%$.
• Untreated DSS can have mortality rates exceeding $20\%$.

Quality of Life

Recovery is usually complete, but the functional capacity can be significantly impaired for 1–2 months due to fatigue and myalgia.

---

Prevention

Primary

• Vector Control: Elimination of breeding sites (Aedes mosquitoes breed in small collections of fresh water). Use of larvicides.
• Personal Protection: Use of mosquito repellents (containing DEET, Picaridin), wearing long sleeves and pants, use of window/door screens, bed nets (though Aedes bite primarily during the day).
• Vaccination (CYD-TDV, Dengvaxia): WHO recommends use only in individuals aged 9–45 years with laboratory-confirmed previous dengue infection and living in endemic areas.

Secondary

• Early Detection: Prompt diagnosis of suspected febrile illness in endemic zones and immediate monitoring for warning signs (especially on Day 3–7).

Tertiary

• Optimal Management of Severe Dengue: Meticulous monitoring and management of fluid dynamics to prevent preventable complications like refractory shock and pulmonary edema.

---

Special Populations

Pediatric

Children, especially infants, are at higher risk for DSS. They have a smaller circulating blood volume relative to mass, making fluid loss rapidly dangerous. Fluid calculations must be precise, based on weight ($\text{mL/kg}$). Signs of shock (narrow pulse pressure, altered mental status) must be recognized early.

Geriatric

Elderly patients often have underlying cardiovascular or renal comorbidities, making them less tolerant of circulatory stress and at higher risk for fluid overload complications (e.g., pulmonary edema). They may have atypical presentations (less prominent fever). Fluid management requires more conservative tapering.

Pregnancy

Dengue infection in the third trimester is associated with a higher risk of premature birth, fetal distress, and vertical transmission (rare). Management is complicated by fluid shifts inherent in pregnancy. Close collaboration between infectious disease specialists and obstetricians is mandatory. Delivery should be avoided during the critical phase if possible due to high risk of hemorrhage.

Comorbidities

Patients with renal failure, heart failure, or severe hypertension require extremely cautious and conservative fluid resuscitation, often requiring hemodynamic monitoring (e.g., CVP, serial ultrasound).

---

Clinical Pearls

Diagnostic

• The "3-5-7" Rule: Fever typically lasts 3 days. The critical plasma leakage phase starts on Day 5 (often corresponding to defervescence). The recovery phase usually begins around Day 7.
• Look for the Hct/Platelet Scissors: The most reliable indicator of impending severe disease is the rapid drop in platelets concurrent with a steep rise in Hct (hemoconcentration).
• Gallbladder Wall Thickening: A highly sensitive sign of systemic capillary leakage detectable by early ultrasound.

Treatment

• No Fluid is Safer than Too Much Fluid: The goal is to provide just enough IV fluid to maintain effective circulation during the leakage phase. Overtreatment is a leading cause of fatal pulmonary edema in the recovery phase.
• Crystalloids are King: Isotonic crystalloids (NS or LR) are the standard of care for initial resuscitation. Colloid use should be limited and reserved for refractory shock with high Hct.
• Transfuse for Bleeding, Not just Low Platelets: Platelet transfusions are generally unnecessary unless massive hemorrhage is occurring or the patient is undergoing an invasive procedure.

Pitfalls

• Treating Fever with NSAIDs: Mismanaging fever with NSAIDs (e.g., ibuprofen) or aspirin greatly increases the risk of hemorrhage.
• Missing the Critical Phase: Clinicians often mistake defervescence (the drop in fever) for improvement, when it is the exact moment plasma leakage begins and the patient is most vulnerable to shock.
• Focusing Solely on Platelets: The most dangerous complication is shock due to plasma leakage, not necessarily hemorrhage (unless massive). Management must prioritize circulatory support.

---

Recent Updates

Guidelines

• WHO 2009 Classification: Remains the functional standard globally, emphasizing prognostic grouping and fluid management based on Hct trend and clinical status.
• Fluid Optimization: Contemporary guidelines stress dynamic, individualized fluid resuscitation guided by physiological parameters and Hct, moving away from fixed volume protocols.

Evidence

• Vaccine Efficacy and Safety: Long-term follow-up confirms that the licensed tetravalent dengue vaccine (Dengvaxia) must only be administered to seropositive individuals due to the risk of ADE in previously unexposed persons. New vaccine candidates are in phase III trials globally.

Controversies

• Role of Corticosteroids: Despite historical use, meta-analyses do not support the use of corticosteroids in severe dengue and may be harmful. Their use is currently discouraged outside of specific immune-mediated complications.
• Optimal Colloid Use: While some guidelines permit specific colloids (e.g., Dextran), disagreement remains regarding their specific benefit over crystalloids and the risk of adverse events.

---

Key References

Guidelines

• World Health Organization (WHO) Guidelines for Diagnosis, Treatment, Prevention and Control (2009). Key reference for the current clinical classification and management scheme.
• CDC Dengue Clinical Guidance.

Studies

• Halstead SB. Dengue and Dengue Hemorrhagic Fever. Reviews the classic understanding of ADE and pathogenesis.
• Nimmannitya S. et al. Dengue Shock Syndrome in Adults: Clinical and Laboratory Findings. Landmark studies reinforcing the importance of plasma leakage.

Reviews

• Whitehorn J, Farrar J. Dengue. Comprehensive reviews published in leading journals (e.g., Lancet, NEJM) providing contemporary updates.